Zolbetuximab (Vyloy) for Gastroesophageal Cancers

This document discusses the implementation of Zolbetuximab (Vyloy®) for the treatment of gastroesophageal cancers through Positive Quality Intervention (PQI) practices. It highlights the role of a multidisciplinary team in administering and managing this therapy, emphasizing the importance of careful patient selection, comprehensive biomarker assessment, and managing side effects such as nausea and vomiting. The document also covers the clinical trials that supported Zolbetuximab’s approval, dosing considerations, and the importance of patient and staff education to optimize treatment outcomes.